YD Bio Limited (YDES)

YD Bio Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Net Income	-3.16	-1.41	0.01	-0.05
Depreciation & Amortization	0.2	0.1	0	0
Other Adjustments	0.04	0.04	0.06	0.12
Change in Receivables	0.08	-0.01	-0.06	0.1
Changes in Inventories	-0.36	0.03	-0.03	-0
Changes in Accounts Payable	0.01	0.01	0.01	-0.02
Changes in Accrued Expenses	0.29	0.21	0	-0.01
Changes in Other Operating Activities	-0.27	-0.81	-0.04	-0.07
Operating Cash Flow	-3.72	-1.84	-0.06	0.07
Capital Expenditures	-0.02	-0.07	-0	-
Purchases of Intangible Assets	-0.04	-2.84	-	-
Purchases of Investments	-	-	-	-0.07
Proceeds from Sale of Investments	-	0.01	-	-
Investing Cash Flow	-0.05	-2.9	-0	-0.07
Long-Term Debt Repaid	-0.02	-0.03	-0.03	-0.03
Net Long-Term Debt Issued (Repaid)	-0.02	-0.03	-0.03	-0.03
Issuance of Common Stock	2.06	7.86	0.05	-
Net Common Stock Issued (Repurchased)	2.06	7.86	0.05	-
Other Financing Activities	-0.56	-0.1	0.09	-0.04
Financing Cash Flow	1.38	7.73	0.11	-0.07
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.08	0.06	-0	-0.01
Net Cash Flow	-2.3	3.05	0.06	-0.08
Free Cash Flow	-3.74	-1.91	-0.06	0.07
FCF Margin	-764.19%	-374.58%	-15.98%	19.22%
Free Cash Flow Per Share	-3739.87	-1911.73	-0.05	-
Levered Free Cash Flow	-3.33	-1.97	-0.08	-0.18
Unlevered Free Cash Flow	-3.41	-2.02	-0.07	-0.14

Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q